 |
5 Products |  |
98 Diseases | | 5 Products |
|
8 Trials |  |
722 News |  |
| «1234 |
- |||| Afrezza (recombinant human insulin inhalation) / MannKind
Enrollment open, Trial initiation date: Study Comparing Prandial Insulin Aspart vs. Technosphere Insulin in Patients With Type 1 Diabetes on Multiple Daily Injections: Investigator-Initiated A Real-life Pilot Study-STAT Study (clinicaltrials.gov) - Sep 12, 2017
P4, N=60, Recruiting, Sponsor: University of Colorado Denver School of Medicine Barbara Davis Center
Not yet recruiting --> Recruiting | Initiation date: Jun 2017 --> Sep 2017
- | Afrezza (recombinant human insulin inhalation) / MannKind
Phase classification, Trial initiation date, Trial primary completion date: Afrezza Safety and Pharmacokinetics Study in Pediatric Patients (clinicaltrials.gov) - Aug 24, 2017
P2, N=46, Not yet recruiting, Sponsor: Mannkind Corporation
Not yet recruiting --> Recruiting | Initiation date: Jun 2017 --> Sep 2017 Phase classification: P1 --> P2 | Initiation date: Oct 2015 --> Sep 2017 | Trial primary completion date: Aug 2017 --> Jul 2020
- | Afrezza (recombinant human insulin inhalation) / MannKind
New P1 trial: Improving Post-Prandial Blood Glucose Control With Afrezza During Closed-Loop Therapy (clinicaltrials.gov) - Jul 30, 2017
P1, N=25, Not yet recruiting, Sponsor: Yale University
- ||||| Afrezza (recombinant human insulin inhalation) / MannKind
New P4 trial: Study Comparing Prandial Insulin Aspart vs. Technosphere Insulin in Patients With Type 1 Diabetes on Multiple Daily Injections: Investigator-Initiated A Real-life Pilot Study-STAT Study (clinicaltrials.gov) - May 8, 2017
P4, N=60, Not yet recruiting, Sponsor: University of Colorado Denver School of Medicine Barbara Davis Center
- Afrezza (recombinant human insulin inhalation) / MannKind
Enrollment change: Feasibility Study Using Zone-MPC Controller, HMS and Technosphere (clinicaltrials.gov) - Apr 21, 2016
P=N/A, N=9, Completed, Sponsor: William Sansum Diabetes Center
Phase classification: P1 --> P2 | Initiation date: Oct 2015 --> Sep 2017 | Trial primary completion date: Aug 2017 --> Jul 2020 N=20 --> 9
- Afrezza (recombinant human insulin inhalation) / MannKind
Enrollment change, Trial suspension: Afrezza Safety and Pharmacokinetics Study in Pediatric Patients (clinicaltrials.gov) - Mar 15, 2016
P1, N=2, Suspended, Sponsor: Sanofi
N=20 --> 9 N=46 --> 2 | Recruiting --> Suspended
- Afrezza (recombinant human insulin inhalation) / MannKind
Enrollment change, Trial initiation date: Evaluate Safety of Technosphere (clinicaltrials.gov) - Feb 16, 2016
P3, N=34, Terminated, Sponsor: Sanofi
N=46 --> 2 | Recruiting --> Suspended N=24 --> 34 | Initiation date: Jun 2008 --> Mar 2009
- | Afrezza (recombinant human insulin inhalation) / MannKind
Trial completion: PK and PD Within-Subject Variability of a Single Dose of Afrezza Inhaled Technosphere Insulin in Patients With Diabetes Mellitus Type 1 (T1DM) (clinicaltrials.gov) - Nov 30, 2015
P1, N=22, Completed, Sponsor: Sanofi
N=24 --> 34 | Initiation date: Jun 2008 --> Mar 2009 Recruiting --> Completed
- | Afrezza (recombinant human insulin inhalation) / MannKind
Trial completion: Single Dose Clamp Study to Evaluate Concentration-time Profile and Metabolic Activity of 3 Dose Levels of Afrezza and 3 Dose Levels of Insulin Lispro in Patients With Type 1 Diabetes Mellitus (clinicaltrials.gov) - Sep 30, 2015
P1, N=30, Completed, Sponsor: Sanofi
Recruiting --> Completed Recruiting --> Completed
- Afrezza (recombinant human insulin inhalation) / MannKind
Enrollment open: Afrezza Safety and Pharmacokinetics Study in Pediatric Patients (clinicaltrials.gov) - Sep 16, 2015
P1, N=46, Recruiting, Sponsor: Sanofi
Recruiting --> Completed Not yet recruiting --> Recruiting
- Afrezza (recombinant human insulin inhalation) / MannKind
Trial primary completion date: Single Dose Clamp Study to Evaluate Concentration-time Profile and Metabolic Activity of 3 Dose Levels of Afrezza and 3 Dose Levels of Insulin Lispro in Patients With Type 1 Diabetes Mellitus (clinicaltrials.gov) - Aug 21, 2015
P1, N=30, Recruiting, Sponsor: Sanofi
Not yet recruiting --> Recruiting Trial primary completion date: Jan 2016 --> Sep 2015
- | Afrezza (recombinant human insulin inhalation) / MannKind
New P1 trial: Afrezza Safety and Pharmacokinetics Study in Pediatric Patients (clinicaltrials.gov) - Aug 18, 2015
P1, N=46, Not yet recruiting, Sponsor: Sanofi
- Afrezza (recombinant human insulin inhalation) / MannKind
Enrollment open: PK and PD Within-Subject Variability of a Single Dose of Afrezza Inhaled Technosphere Insulin in Patients With Diabetes Mellitus Type 1 (T1DM) (clinicaltrials.gov) - Jul 29, 2015
P1, N=22, Recruiting, Sponsor: Sanofi
Trial primary completion date: Jan 2016 --> Sep 2015 Not yet recruiting --> Recruiting
- Afrezza (recombinant human insulin inhalation) / MannKind
Enrollment open: Single Dose Clamp Study to Evaluate Concentration-time Profile and Metabolic Activity of 3 Dose Levels of Afrezza and 3 Dose Levels of Insulin Lispro in Patients With Type 1 Diabetes Mellitus (clinicaltrials.gov) - Jul 12, 2015
P1, N=30, Recruiting, Sponsor: Sanofi
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- | Afrezza (recombinant human insulin inhalation) / MannKind
New P1 trial: PK and PD Within-Subject Variability of a Single Dose of Afrezza Inhaled Technosphere Insulin in Patients With Diabetes Mellitus Type 1 (T1DM) (clinicaltrials.gov) - Jun 30, 2015
P1, N=22, Not yet recruiting, Sponsor: Sanofi
- | Afrezza (recombinant human insulin inhalation) / MannKind
New P1 trial: Single Dose Clamp Study to Evaluate Concentration-time Profile and Metabolic Activity of 3 Dose Levels of Afrezza and 3 Dose Levels of Insulin Lispro in Patients With Type 1 Diabetes Mellitus (clinicaltrials.gov) - Jun 12, 2015
P1, N=30, Not yet recruiting, Sponsor: Sanofi
- || Afrezza (recombinant human insulin inhalation) / MannKind
Trial completion: Patient Transitioning From Exubera (clinicaltrials.gov) - May 16, 2015
P3, N=16, Completed, Sponsor: Mannkind Corporation
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- | Afrezza (recombinant human insulin inhalation) / MannKind
Trial completion: Compare the Same Dosage of Insulin Using a Combination of Cartridges, 30 Units as 2 Cartridges vs. 1 Cartridge (clinicaltrials.gov) - Dec 13, 2014
P1, N=40, Completed, Sponsor: Mannkind Corporation
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | Afrezza (recombinant human insulin inhalation) / MannKind
Enrollment change: Effects of URI on Diabetic Subjects Utilizing Technosphere Insulin After a Meal Challenge (clinicaltrials.gov) - Dec 7, 2014
P2, N=20, Completed, Sponsor: Mannkind Corporation
Active, not recruiting --> Completed N=50 --> 20
- | Afrezza (recombinant human insulin inhalation) / MannKind
Trial completion, Trial primary completion date: Feasibility Study Using Zone-MPC Controller, HMS and Technosphere (clinicaltrials.gov) - Nov 18, 2014
P=N/A, N=20, Completed, Sponsor: William Sansum Diabetes Center
N=50 --> 20 Active, not recruiting --> Completed | Trial primary completion date: Dec 2013 --> Jun 2013
- Afrezza (recombinant human insulin inhalation) / MannKind
Enrollment change, Trial termination, Trial primary completion date: Evaluate Safety of Technosphere (clinicaltrials.gov) - Oct 24, 2014
P3, N=24, Terminated, Sponsor: Mannkind Corporation
Active, not recruiting --> Completed | Trial primary completion date: Dec 2013 --> Jun 2013 N=510 --> 24 | Recruiting --> Terminated | Trial primary completion date: Aug 2015 --> Nov 2014; Terminated upon recommendation of the Data Safety Monitoring Board (DSMB)
- Afrezza (recombinant human insulin inhalation) / MannKind
Trial termination: Safety and Efficacy of Technosphere (clinicaltrials.gov) - Oct 22, 2014
P2, N=18, Terminated, Sponsor: Mannkind Corporation
N=510 --> 24 | Recruiting --> Terminated | Trial primary completion date: Aug 2015 --> Nov 2014; Terminated upon recommendation of the Data Safety Monitoring Board (DSMB) Completed --> Terminated; Business reasons
- | Afrezza (recombinant human insulin inhalation) / MannKind
Trial termination, Combination therapy: Safety and Efficacy of Technosphere (clinicaltrials.gov) - Oct 17, 2014
P3, N=130, Terminated, Sponsor: Mannkind Corporation
Completed --> Terminated; Business reasons Completed --> Terminated; Sponsor stopped development of the MedTone inhaler in favor of an improved device (Gen2 inhaler)
- | Afrezza (recombinant human insulin inhalation) / MannKind
Trial completion, Trial primary completion date: A Study Designed to Compare 2 Dose Strengths of TI Inhalation Powder in Adults With Type 1 Diabetes Mellitus and to Compare One of Those Formulations (30Units) With an Injection of Insulin Lispro (clinicaltrials.gov) - Oct 17, 2014
P2, N=29, Completed, Sponsor: Mannkind Corporation
Completed --> Terminated; Sponsor stopped development of the MedTone inhaler in favor of an improved device (Gen2 inhaler) Not yet recruiting --> Completed | Trial primary completion date: Jul 2008 --> Nov 2008
- | Afrezza (recombinant human insulin inhalation) / MannKind
Trial completion: Comparison of 30 Units of TI (Technosphere (clinicaltrials.gov) - Oct 2, 2014
P1, N=38, Completed, Sponsor: Mannkind Corporation
Not yet recruiting --> Completed | Trial primary completion date: Jul 2008 --> Nov 2008 Active, not recruiting --> Completed
- Afrezza (recombinant human insulin inhalation) / MannKind
Trial completion date: Compare the Same Dosage of Insulin Using a Combination of Cartridges, 30 Units as 2 Cartridges vs. 1 Cartridge (clinicaltrials.gov) - May 19, 2014
P1, N=36, Active, not recruiting, Sponsor: Mannkind Corporation
Active, not recruiting --> Completed Trial completion date: May 2014 --> Aug 2014
- Afrezza (recombinant human insulin inhalation) / MannKind
Enrollment closed: Comparison of 30 Units of TI (Technosphere (clinicaltrials.gov) - Mar 10, 2014
P1, N=36, Active, not recruiting, Sponsor: Mannkind Corporation
Trial completion date: May 2014 --> Aug 2014 Recruiting --> Active, not recruiting
- | MKC-1106 / MannKind
Trial completion, Metastases: Vaccine Therapy in Treating Patients With Stage IV Melanoma (clinicaltrials.gov) - Feb 22, 2014
P1/2, N=19, Completed, Sponsor: Mannkind Corporation
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- Afrezza (recombinant human insulin inhalation) / MannKind
Enrollment closed: Compare the Same Dosage of Insulin Using a Combination of Cartridges, 30 Units as 2 Cartridges vs. 1 Cartridge (clinicaltrials.gov) - Dec 1, 2013
P1, N=36, Active, not recruiting, Sponsor: Mannkind Corporation
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- | Afrezza (recombinant human insulin inhalation) / MannKind
New P1 trial: Comparison of 30 Units of TI (Technosphere (clinicaltrials.gov) - Nov 11, 2013
P1, N=36, Active, not recruiting, Sponsor: Mannkind Corporation
- ||||||| Afrezza (recombinant human insulin inhalation) / MannKind
Trial completion: Comparison of Technosphere (clinicaltrials.gov) - Aug 18, 2013
P3, N=353, Completed, Sponsor: Mannkind Corporation
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- ||||||| Afrezza (recombinant human insulin inhalation) / MannKind
Trial completion, Combination therapy: Clinical Trial Evaluating Technosphere (clinicaltrials.gov) - Aug 18, 2013
P3, N=518, Completed, Sponsor: Mannkind Corporation
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | Afrezza (recombinant human insulin inhalation) / MannKind
New P1 trial: Compare the Same Dosage of Insulin Using a Combination of Cartridges, 30 Units as 2 Cartridges vs. 1 Cartridge (clinicaltrials.gov) - Jul 16, 2013
P1, N=36, Active, not recruiting, Sponsor: Mannkind Corporation
- ||| Afrezza (recombinant human insulin inhalation) / MannKind
New P3 trial: Patient Transitioning From Exubera (clinicaltrials.gov) - Feb 24, 2013
P3, N=16, Active, not recruiting, Sponsor: Mannkind Corporation
- Afrezza (recombinant human insulin inhalation) / MannKind
Trial initiation date: Single Site, Single Subject, Treatment IND With Mannkind Corporation's Technosphere Inhalation System (clinicaltrials.gov) - Feb 5, 2013
P=N/A, N=1, Not yet recruiting, Sponsor: South Orange County Endocrinology
Active, not recruiting --> Completed Initiation date: Oct 2011 --> May 2013
- | Afrezza (recombinant human insulin inhalation) / MannKind
Trial completion: Comparison of Technosphere Insulin Inhalation Powder & Subcutaneous Rapid-Acting Analog in Subjects With Type 1 Diabetes (clinicaltrials.gov) - Jan 23, 2013
P1, N=17, Completed, Sponsor: Mannkind Corporation
Initiation date: Oct 2011 --> May 2013 Active, not recruiting --> Completed
- | Afrezza (recombinant human insulin inhalation) / MannKind
Trial completion: Healthy Normal Volunteers Looking at Exposure and Effects of Multiple Doses of Technosphere (clinicaltrials.gov) - Sep 4, 2012
P1, N=35, Completed, Sponsor: Mannkind Corporation
Active, not recruiting --> Completed Active, not recruiting --> Completed
- Afrezza (recombinant human insulin inhalation) / MannKind
Enrollment change: A Study Designed to Determine if the Pharmacokinetic Disposition of Inhaled Insulin Exposure is the Same for Asthmatics and Non-asthmatics (clinicaltrials.gov) - Jun 11, 2012
P1, N=30, Completed, Sponsor: Mannkind Corporation
Active, not recruiting --> Completed N=24 --> 30
- Afrezza (recombinant human insulin inhalation) / MannKind
Trial termination, Combination therapy: Clinical Trial Evaluating the Efficacy and Safety of Technosphere (clinicaltrials.gov) - May 8, 2012
P3, N=39, Terminated, Sponsor: Mannkind Corporation
N=24 --> 30 Active, not recruiting --> Terminated; For Business Reasons
- Afrezza (recombinant human insulin inhalation) / MannKind
Enrollment change: Inhaled Technosphere Insulin in Subjects With Diabetes Mellitus and Asthma (clinicaltrials.gov) - May 2, 2012
P3, N=3, Terminated, Sponsor: Mannkind Corporation
Active, not recruiting --> Terminated; For Business Reasons N=193 --> 3
- | Afrezza (recombinant human insulin inhalation) / MannKind
New P1 trial: Comparison of Technosphere Insulin Inhalation Powder & Subcutaneous Rapid-Acting Analog in Subjects With Type 1 Diabetes (clinicaltrials.gov) - Mar 4, 2012
P1, N=17, Completed, Sponsor: Mannkind Corporation
- | Afrezza (recombinant human insulin inhalation) / MannKind
New P1 trial: Healthy Normal Volunteers Looking at Exposure and Effects of Multiple Doses of Technosphere (clinicaltrials.gov) - Dec 11, 2011
P1, N=35, Completed, Sponsor: Mannkind Corporation
- MKC-1106 / MannKind
Trial termination, IO biomarker, Metastases: Safety, Immune and Tumor Response to a Multi-component Immune Based Therapy (MKC1106-MT) for Patients With Melanoma (clinicaltrials.gov) - Oct 18, 2011
P2, N=5, Terminated, Sponsor: Mannkind Corporation
N=193 --> 3 Active, not recruiting --> Terminated; Financial/Business Reasons
- MKC-1106 / MannKind
Enrollment change, IO biomarker, Metastases: Safety, Immune and Tumor Response to a Multi-component Immune Based Therapy (MKC1106-MT) for Patients With Melanoma (clinicaltrials.gov) - Oct 18, 2011
P2, N=5, Terminated, Sponsor: Mannkind Corporation
Active, not recruiting --> Terminated; Financial/Business Reasons N=44 --> 5
- |||||||||| Afrezza (recombinant human insulin inhalation) / MannKind
New P3 trial: Comparison of Technosphere (clinicaltrials.gov) - Oct 11, 2011
P3, N=353, Completed, Sponsor: Mannkind Corporation
- |||||||||| Afrezza (recombinant human insulin inhalation) / MannKind
New P3 trial, Combination therapy: Clinical Trial Evaluating Technosphere (clinicaltrials.gov) - Oct 2, 2011
P3, N=518, Completed, Sponsor: Mannkind Corporation